)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Elicio Therapeutics
Elicio Therapeutics (ELTX) investor relations material
Elicio Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
AMPLIFY-7P missed its primary intent-to-treat DFS endpoint, while subgroup and adjusted analyses showed favorable outcomes with camupepimut; findings are informing a targeted adjuvant PDAC Phase 3 strategy.
A Phase 1 metastatic KRAS-mutated PDAC combination study is planned for Q4 2026; $30.9M in cash and cash equivalents was expected to fund operations into Q2 2027.
Financial highlights
Q3 2026 operating expenses were $8.5M vs. $8.0M YoY; net loss was $8.0M vs. $10.1M. 9M operating expenses were $29.5M vs. $28.9M, and net loss was $28.0M vs. $31.9M.
Q3 R&D expense was $4.9M vs. $5.0M YoY and G&A was $3.6M vs. $3.0M; 9M R&D was $18.5M vs. $19.8M and G&A was $11.0M vs. $9.0M.
Cash and cash equivalents were $30.9M at September 30, 2026, vs. $18.6M at December 31, 2025; accumulated deficit was $261.7M.
9M net cash used in operations was $30.2M; net cash provided by financing was $42.3M, contributing to a $12.1M increase in cash and cash equivalents plus restricted cash.
Outlook and guidance
Cash and cash equivalents are expected to fund planned operations into Q2 2027 under the current operating plan; estimates depend on spending and program progress.
A Phase 1 metastatic KRAS-mutated PDAC study of camupepimut with daraxonrasib, with or without nivolumab, is targeted to start in Q4 2026; preliminary readouts are expected three to six months after study start.
Phase 2 analyses are intended to guide patient stratification and dosing for a potential Phase 3 adjuvant PDAC study; its design remains subject to regulatory discussions, development planning and financing.
R&D, G&A and capital expenditures are expected to rise as clinical programs advance; continued net losses and additional financing needs are anticipated.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elicio Therapeutics
- Camუpepimut showed immune activity and promising follow-on responses despite a missed primary Phase 2 endpoint.ELTX
Investor presentation - Three director elections and auditor ratification headline a proxy with major governance and financing details.ELTXProxy filing
- ELI-002 immunotherapy shows strong early results and is advancing to new combination trials in KRAS cancers.ELTXH.C. Wainwright 28th Annual Global Investment Conference
- Lymph node-targeted immunotherapy achieved rare, durable complete responses in mKRAS PDAC.ELTXCorporate presentation
- ELI-002 7P achieved rare complete responses in metastatic PDAC and improved DFS in adjuvant settings.ELTXCorporate presentation
- Planned Phase 1 trial for ELI-002 7P follows positive responses; cash runway into Q1 2027.ELTXQ2 2026
- Durable complete responses observed after ELI-002 7P and checkpoint inhibition in metastatic PDAC.ELTXCorporate presentation
- Rare, durable complete responses after ELI-002 and checkpoint inhibition prompt Phase 1 study.ELTXKOL event
- ELI-002 7P delivers robust, durable immune responses in mKRAS cancers with strong clinical potential.ELTXCorporate presentation
Next Elicio Therapeutics earnings date
KOL event11 Nov, 2026
Elicio Therapeutics
Next Elicio Therapeutics earnings date
KOL event11 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Elicio Therapeutics Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. The company specializes in AMP (Amphiphile) platform technology, designed to enhance the delivery of cancer vaccines and immunomodulators to the lymphatic system, improving immune response. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.